We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Roche Sells Drugs of Abuse Testing Business to Varian

By HospiMedica staff writers
Posted on 12 Feb 2003
In a move to divest a business whose market is not important to the company's current strategy, Roche Diagnostics (Basel, Switzerland) has sold its worldwide nonclinical drugs of abuse testing (DAT) business to Varian, Inc. (Palo Alto, CA) for an undisclosed amount.

Included in the sale were Roche's OnTrak TesTcup, OnTrak TesTstik, OnSite alcohol and Intect line of testing devices, all commonly used for illicit drug screening in the workplace and in the criminal justice system. The sale does not include Roche's drugs of abuse testing products used by clinical and hospital laboratory customers. Roche will continue to sell and support the OnTrak TesTcard 9 drugs of abuse testing product and all Abuscreen Online assays for drug abuse.

"When reviewing other companies who were interested in purchasing this business, we sought buyers who were closely aligned with the marketplace to continue growing this business,” said Martin Madaus, president and CEO of Roche Diagnostics, North America.





Related Links:
Roche Diagnostics
Varian

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Multi-Chamber Washer-Disinfector
WD 390
New
Urine Analyzer
respons® UDS100

Latest Industry News

Integrated DNA Technologies Expands into Clinical Diagnostics
12 Feb 2003  |   Industry

Co-Diagnostics Agreement Expands Commercial and Distribution Reach in South Asia
12 Feb 2003  |   Industry

Automated MSI Test Gains IVDR Certification to Guide CRC Therapy
12 Feb 2003  |   Industry



INTEGRA BIOSCIENCES AG